Celebrating Six Years of Innovation at MAIA Biotechnology! Today we commemorate a significant milestone for MAIA as we celebrate six years of pioneering research and development. From humble beginnings in 2018, MAIA has since evolved into a dynamic organization with a robust pipeline of telomere-targeting therapies for cancer treatment. We've achieved numerous milestones, including establishing strategic partnerships, conducting successful clinical trials, and expanding our global reach. Here’s a recap of achievements in 2024 so far: • Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial • Most recent data showed THIO’s strong outperformance against standard-of-care treatments in #NSCLC • 38% ORR in third-line NSCLC patients (THIO 180mg) vs. ~6% for currently available treatments in a similar population • 5.5 months median progression-free survival also in third-line NSCLC, more than double PFS of current chemotherapy treatments • Secured continued insider investment through independent board members’ participation in private placement equity financings • Funding of more than $12M year-to-date, including $7.4 million in Q2’24 Thanks to the brilliant minds of Dr. Vlad Vitoc, MD, MBA, Dr. Jerry Shay, and Dr. Sergei Gryaznov, and the unwavering dedication of our entire team, we've made remarkable strides. We would also like to thank our investors and partners for your continued support. As we look ahead, we remain committed to our mission. Here's to many more years of innovation and success! #CancerResearch #Biotech #Innovation
Bravo Dr. Vlad Vitoc, MD, MBA, Dr. Sergei Gryaznov, and Dr. Jerry Shav for your dedication, instrumental leadership, and relentless clinical research fighting cancer!
Innovation always inspires! Congratulation for the achieved results!
Great work Vlad! I knew you when.....
Congratulations Vlad!
Head of Listings, NYSE American. NYSE | IntercontinentalExchange
2moIt's wonderful to see this scientific progress by MAIA Biotechnology, Inc. From the NYSE, thank you Vlad Vitoc, MD, MBA and team!